Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Moderna

Novavax Stock Dips As Moderna's Woes Weigh On Vaccine Sector

Shares of Novavax Inc (NASDAQ:NVAX) are trading lower Friday morning, appearing to be caught in a downdraft affecting COVID-19 vaccine makers after rival Moderna Inc (NASDAQ:MRNA) reported disappointing second-quarter financial results and cut its full-year forecast.

Benzinga

Moderna's Key Patent Win Overshadowed By Gloomy Outlook

Moderna Inc. (NASDAQ:MRNA) reported on Friday a second-quarter loss of $2.13 per share, beating the consensus of a $2.98 loss, an improvement from a loss of $3.33 a year ago.

Benzinga

Moderna Earnings Are Imminent; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Moderna, Inc. (NASDAQ:MRNA) will release earnings results for the second quarter, before the opening bell on Friday, Aug. 1.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Moderna Announces 10% Workforce Cut Amid Declining COVID-19 Vaccine Sales, Regulatory Hurdles

Moderna Inc. (NASDAQ:MRNA) has announced plans to reduce its global workforce by approximately 10% by the end of the year due to decreasing COVID-19 vaccine sales and market uncertainty.

Benzinga

1 Analyst Thinks This Former Pandemic Winner Could Surge 500% This Year

This risky biotech company faces significant challenges ahead. But it has already proven its worth and may be able to do so again.

Barchart

What's Going On With Moderna Stock Wednesday?

Moderna Inc.’s (NASDAQ:MRNA) stock has surged approximately 37% in the last month but has dipped around 15% year to date.

Benzinga

What to Expect From Moderna's Next Quarterly Earnings Report

Moderna is expected to announce its second-quarter results in the upcoming month, and analysts expect a slight reduction in its losses.

Barchart

Read news from The Economist, FT, and more,
with one subscription

‘Tremendous uncertainty’ for cancer research as US officials target mRNA vaccines

Amid Trump cuts and state-level backlash, experts worry that progress in messenger RNA vaccines could stall

The Guardian - US

FDA Grants Complete Approval To Moderna's COVID-19 Vaccine For Children As Young As 6 Months

The U.S. Food and Drug Administration (FDA) has approved Moderna Inc.’s (NASDAQ:MRNA) supplemental Biologics License Application (sBLA) for Spikevax, the company’s COVID-19 vaccine, in children six months through 11 years of age who are at increased risk for COVID-19 disease.

Benzinga

The Next Moderna? This Clinical-Stage Biotech Has Breakout Potential.

This clinical-stage biotech stock has a strong pipeline capable of creating the next Moderna.

Barchart

FDA vaccine official restricted COVID vaccine approvals against the advice of agency staff

A top official at the Food and Drug Administration recently overruled government scientists on the availability of two COVID-19 vaccines

The Independent UK

RFK Jr.'s made promises about vaccines. Here's what he's done as health secretary

The Department of Health and Human Services under Robert F

The Independent UK

COVID Vaccine Side Effects: FDA Announces Rare Heart-Related Reactions - What You Should Know

FDA has updated safety warnings for the Pfizer-BioNTech (Comirnaty) and Moderna (Spikevax) COVID-19 vaccines.

International Business Times UK

RFK Jr. Overhauls CDC Vaccine Panel, Sparking Expert Backlash, Boycott From Top Medical Group

Health Secretary Robert F. Kennedy Jr.'s newly reconstituted vaccine advisory panel is facing criticism from medical experts and former federal officials after its first meeting strayed sharply from established scientific review norms.

Benzinga

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - US

US experts fear all vaccines at risk as Trump officials target mRNA jabs

Administration’s actions signal move away from technology as health agencies see vaccine-related shakeups

Barchart

How Is Moderna’s Stock Performance Compared to Other Biotechnology Stocks?

Moderna has significantly underperformed other biotechnology stocks over the past year, and analysts remain cautious on the stock’s prospects.

Fortune

What you need to know about Moderna's new COVID vaccine, just approved by the FDA

The shot had previously been approved for everyone 12 and older. Now, there are limits.

The Independent UK

FDA approves Moderna's new lower-dose COVID-19 vaccine

The Food and Drug administration has approved a new COVID-19 vaccine made by Moderna but with limits on who can use it

Get all your
news in one place.

100’s of premium titles.
One news app.

The Independent UK

HHS cancels funding for bird flu vaccine development because of RNA concerns

The Trump administration said the move signals a ‘shift in federal vaccine funding priorities’

International Business Times

Moderna Loses $700M US Contract for Bird Flu Vaccine Development

Moderna loses $700 million U.S. contract to develop bird flu vaccine after government review ends funding.

The Independent UK

Trump administration cancels $766 million Moderna contract to fight pandemic flu

The Trump administration has canceled $766 million awarded to drugmaker Moderna Inc. to develop a vaccine against potential pandemic influenza viruses, including H5N1 bird flu

The Independent UK

FDA panel debates COVID vaccine recipe as questions swirl about fall shots

Government vaccine advisers are meeting to decide if the recipe for COVID-19 vaccines needs updating for this fall and winter

MarketBeat

Moderna Stock Looks Ripe for a Short Squeeze

Moderna stock has made single-digit gains in the last month, and high short interest suggests that any bullish news could cause a short squeeze

Barchart

Moderna Is the Largest of Barchart’s Bottom 100 Stocks to Buy—But Size Alone Isn’t a Reason to Invest

Moderna is the largest market cap in Barchart’s Bottom 100 Stocks to Buy. On Monday, the vaccine maker moved seven spots to the 86th position. You don’t want to make this list if you are the CEO. Here’s why.

Fortune

This Moderna leader uses AI to resolve conflict on the executive team—all before it even happens

“I think I’m pretty good with people, but it gives me an advantage that I didn’t have before.”

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the Food and Drug Administration

196 stories

GPT

130 stories

the Department of Health and Human Services

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.